AI Insight
Chronic kidney disease is now understood as a multisystem condition that shares inflammatory, metabolic, and fibrotic pathways with cardiovascular disease, diabetes, obesity, and infection. New therapeutic agents including SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and GLP receptor agonists have demonstrated significant benefits in slowing CKD progression and improving cardiovascular outcomes. Combination treatment strategies using these novel therapeutics show additive potential for enhanced clinical benefits.
Why it matters
These advances represent a paradigm shift in CKD management, moving from treating kidney disease in isolation to addressing interconnected metabolic and cardiovascular pathways. The availability of multiple effective therapeutic options, particularly in combination, offers new hope for millions of patients with CKD and related comorbidities.
Chronic kidney disease (CKD) is increasingly recognised as a complex, multisystem condition that rarely occurs in isolation. This Series paper outlines major advances in therapeutics that target shared inflammatory, metabolic, and fibrotic pathways across CKD, cardiovascular disease, diabetes, obesity, and infection. Novel therapeutics, including SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and GLP receptor agonists, show substantial benefits for slowing CKD progression and improving cardiovascular outcomes, with combination strategies showing additive potential.